The Protein-Tyrosine Kinase Substrate, p81, Is Homologous to a Chicken Microvillar Core Protein

Kathleen L. Gould, Jonathan A. Cooper, Anthony Bretscher, and Tony Hunter

*Molecular Biology and Virology Laboratory, The Salk Institute, San Diego, California 92138; Department of Biology, University of California at San Diego, La Jolla, California 92093; Fred Hutchinson Cancer Research Center, Seattle, Washington 98104; and Section of Biochemistry, Molecular, and Cell Biology, Cornell University, Ithaca, New York 14853

Abstract. p81, a protein-tyrosine kinase substrate previously identified in epidermal growth factor-treated A431 cells, is demonstrated to be homologous to ezrin, a 80-kD component of microvillar core proteins. p81 has been characterized using antiserum raised against purified chicken intestinal ezrin. p81, located by indirect immunofluorescent staining, is concentrated in surface projections of A431 cells such as microvilli and retraction fibers. None of the conditions of biochemical cell fractionation tested completely solubilizes p81; the insoluble p81 partitions as if associated with the cytoskeleton. The soluble form of p81 behaves as a monomer in all extraction procedures studied. EGF-stimulated phosphorylation of p81 does not appear to change its intracellular location. p81 exhibits a wide tissue distribution with highest levels of expression in small intestine, kidney, thymus, and lung. Intermediate levels are found in spleen, thymus, lymph nodes, and bone marrow, with low levels in brain, heart, and testes. p81 is undetectable in muscle and liver. In A431 cells, p81 is phosphorylated on serine and threonine residues. Upon EGF treatment, ~10% of p81 becomes phosphorylated on tyrosine, and the phosphorylation of threonine residues increases.

PHOSPHORYLATION of proteins on tyrosine residues is a rare event in most normal cells (33). However, cells respond to the growth factors, epidermal growth factor (EGF) and platelet-derived growth factor, with an increase in protein-tyrosine kinase activity as manifested by an elevation of phosphotyrosine in cellular protein (10, 34). There is a similar 5-10-fold increase in the phosphotyrosine content of cells transformed by acutely oncogenic retroviruses that encode protein-tyrosine kinases (33, 35, 50). Incubation of some normal cell lines with sodium orthovanadate, an inhibitor of phosphotyrosine-specific phosphatases, also leads to an increase in cellular phosphotyrosine and to transformation (39). These data suggest that phosphorylation of cellular proteins on tyrosine is involved in controlling cell growth and transformation (50). Some protein-tyrosine kinase substrates are likely to be proteins directly involved in regulating these processes.

Few substrate proteins for protein-tyrosine kinases have been identified. Three, lactate dehydrogenase, phosphoglycerate mutase, and enolase, are phosphorylated in transformed chick cells and have known enzymatic functions (15). However, it has not yet been possible to demonstrate a change in function accompanying their phosphorylation. Other cellular proteins found to contain phosphotyrosine are vinculin (51, 52), and five proteins identified by their apparent molecular masses: p50 (5, 33, 46), p42 (18, 26, 40, 43), p36 (9, 10, 21, 34, 47), p35 (23), p81 (12, 13, 16, 34, 36), and p41 (10; Freed, E., personal communication). Functions have not yet been assigned to these latter proteins, and thus it has been difficult to assess the effect, if any, of their phosphorylation on cellular phenotype. Much work has been directed toward understanding the function of these proteins to ascertain whether their phosphorylation plays a role in transformation, mitogenesis, or differentiation.

In this study we demonstrate that p81 is homologous to an 80-kD protein purified from chicken intestinal epithelial cells (3, 4). This 80-kD protein, now called ezrin, is a minor component of the isolated microvillar cores of these brush border cells (3). Its location suggests it plays a structural role, but its exact function is not yet clear. Ezrin is present in a wide variety of cultured cells where it has been localized to cell surface structures (3). Phosphorylated p81 (p(p81)) was first detected in A431 cells, a human epidermoid carcinoma cell line, where a large increase in its phosphotyrosine content was observed after EGF treatment (34). Phosphotyrosine...
containing pp81 was also detected in Snyder-Theilen–feline sarcoma virus (ST–FeSV) transformed A431 cells and ST–FeSV transformed NIH 3T3 cells (16, 36). The homology between ezrin and p81 has allowed us to study the intracellular location and tissue distribution of p81 and compare it with that of another protein-tyrosine kinase substrate, p36. In addition, we have characterized the phosphorylation sites in pp81 from A431 cells.

**Materials and Methods**

**Cells and Antisera**

A431 cells were grown in Dulbecco’s modified Eagle’s medium (DME) supplemented with 10% calf serum. LIM1215 cells (55), a human coloncic tumor line, were grown in RPMI supplemented with 10% fetal calf serum, 0.6 μg/ml insulin, 1 μg/ml dexamethasone, and 10^{-5} M α-thioglycerol. Rabbit anti-ezrin serum was prepared against purified chick intestinal ezrin as previously reported (3). Antiserum was used at a 1:200 dilution for Western blotting, and immunoprecipitations were performed with antisera in excess. For use in indirect immunofluorescence and indirect immunoperoxidase staining, anti-ezrin IgG was affinity purified as described and used at 32 μg/ml (3). Anti-p36 serum was prepared against partially purified chicken fibroblast protein and used as previously reported (14). Anti-fodrin serum was prepared against purified porcine brain fodrin (28) and was used in excess for immunoprecipitation.

**Biosynthetic Labeling and Immunoprecipitation**

Subconfluent cells were labeled by incubation with 50 μCi/ml or 1 μCi/ml for peptide mapping [35S]methionine (>1,000 Ci/mmol, Amersham Corporation, Arlington Heights, IL) at 37°C for 18 h in methionine-free DME supplemented with 5% calf serum and 5% DME or by incubation with 2–3 μCi/ml [35S]orthophosphate (ICN Radiochemicals, Irvine, CA) at 37°C for 16–18 h in phosphate-free DME supplemented with 4% calf serum. Where indicated, EGF (Potter, S., The Salk Institute) was added at 60 ng/ml for 10 min at the end of the labeling period. Cells were washed three times in cold Tris-buffered saline before solubilization in either 400 μl for each 35-mm dish of cold RIPAVF buffer (10 mM sodium phosphate, pH 7.0, 0.1 M NaCl, 1% SDS, 1% Nonidet P-40, 0.1% sodium deoxycholate, 1% Trasylol (Mobay Chemical Corp., Pittsburgh, PA), 2 mM EDTA, 100 μM Na3VO4, and 50 mM NaF) or 100 μl for each 35-mm dish of SDS lysis buffer (10 mM sodium phosphate, pH 7.2, 0.5% SDS, 1 mM EDTA, 1 mM dithiothreitol, and 1% Trasylol). In the latter case, the lystate was prepared at room temperature and heated for 2 min at 100°C. 3 vol of cold RIPAVF was then added before centrifugation (20,000 g for 60 min at 4°C) and immunoprecipitation of the supernatant. Immunoprecipitations were performed as previously described (49). Alkali treatment of SDS gels was performed as detailed earlier (17).

**Quantitation of p81 in A431 Cells**

p81 was immunoprecipitated from lysates of A431 cells labeled for 18 h with [35S]methionine using excess anti-ezrin serum. Immunoprecipitates were resolved on SDS polyacrylamide gels that were impregnated with 2,5-diphenyloxazole. p81 was detected by fluorography, and gel bands corresponding to p81 were cut out and dissolved in 0.2 ml 70% perchloric acid and 0.4 ml 30% H2O2 overnight at 60°C before scintillation counting. The ratio of recovered counts in each protein band to the total acid-precipitable counts used for immunoprecipitation gave an estimate of the abundance of p81.

**Gel Electrophoresis and Western Blots**

Two-dimensional gel sample preparation and one- and two-dimensional electrophoresis were performed as reported elsewhere (8, 24, 30). Isoelectric focusing was performed with pH 6–8 or pH 6–8/10 range ampholytes. A detailed account of the Western blotting procedure was described previously (30). SDS gels were silver stained as reported (42).

**Phosphoamino Acid Analysis and Tryptic Peptide Mapping**

Immunoprecipitated proteins were resolved on one-dimensional gels, extracted, and subjected to either phosphoamino acid analysis or tryptic digestion (2, 17, 33). Phosphoamino acids were resolved in two dimensions by electrophoresis on 100-μm cellulose thin-layer plates at pH 1.9, followed by electrophoresis at right angles at pH 3.5. Phosphopeptides were resolved in two dimensions on 100-μm cellulose thin-layer plates by electrophoresis at pH 1.9 for 25 min at 1 kV followed by chromatography (33). [35S]Methionine-labeled peptides were resolved by electrophoresis at pH 4.7 for 27 min at 1 kV followed by chromatography (2).

**Immunofluorescence Staining**

A431 cells were cultured on 22-mm square glass coverslips (some precoated with poly-L-lysine) for 40 h before use. They were fixed in phosphate-buffered saline (PBS) containing 3% formaldehyde for 10 min at 25°C, washed three times (5 min each wash) with PBS, permeabilized for 5 min in ice cold 20 mM Hepes, pH 7.4, 0.5% Triton X-100, 300 mM sucrose, 3 mM MgCl2, 50 mM NaCl, and rinsed three times for 5 min with PBS. The coverslips were incubated with 20–30 μl of affinity-purified anti-ezrin IgG at 32 μg/ml for 30 min at room temperature, washed three times with PBS for 20 min, and then incubated with 20–30 μl of a 1:15 dilution of affinity-purified fluorescein-conjugated goat anti-rabbit IgG (Sigma Chemical Co., St. Louis, MO). The coverslips were washed three times with PBS for 20 min and mounted on glass slides with 10 mM Tris-HCl, pH 7.4, 0.2 M NaCl, and 90% glycerol. They were viewed with a Nikon Optiphot microscope (Nikon Inc., Garden City, NY) with episcopic fluorescence attachment through a Plan Apo 40x oil objective. Photographs were taken with a Kodak Tri-X film.

**Cell Fractionation into Soluble and Particulate Fractions**

A431 cells (35-mm dishes) were washed twice with cold Tris-buffered saline. The cells were allowed to swell for 10 min at 4°C in 0.4 ml of a solution containing 20 mM sodium phosphate pH 7.0, 10 mM NaCl, 10 mM NaF, 100 μM Na3VO4, 1% Trasylol, 14 mM 2-mercaptoethanol, and either 1 mM EDTA or 1 mM MgCl2. They were scraped off the dish and transferred to a Teflon tissue grinder (Dual size 20, Kontes Co., Vineland, NJ) and homogenized with 25 strokes. Cell breakage was monitored by light microscopy. The homogenate was transferred to airfuge tubes and centrifuged in an Airfuge (Beckman Instruments, Inc., Palo Alto, CA) at 100,000 g for 15 min. The pellets were resuspended in the original volume of swelling buffer, and both pellet and supernatant fractions were adjusted to RIPAVF conditions.

**Cell Fractionation into Detergent Soluble and Insoluble Fractions**

Three procedures were used to define detergent-soluble and insoluble fractions: (a) A431 cells (35-mm dishes) were extracted on the dish for 3 min at 4°C with 100 μl of ice-cold 10 mM Pipes pH 6.8, 1% Triton X-100, 100 mM KCl, 300 mM sucrose, 50 mM NaF, 100 μM Na3VO4, 2.5 mM MgCl2, 1 mM CaCl2, and 1% Trasylol. Dishes were drained and washed once with 300 μl of additional buffer. Insoluble material was scraped into 400 μl buffer. (b) Same as a except that the extraction buffer was ice-cold 10 mM Pipes pH 6.8, 0.5% Nonidet P-40, 100 mM KCl, 300 mM sucrose, 50 mM NaF, 100 μM Na3VO4, 3 mM MgCl2, and 1% Trasylol. (c) Same as a except that the extraction buffer was ice-cold 10 mM 2-N-morpholinoethane sulfonic acid pH 6.2, 10 mM NaCl, 50 mM Pipes, 100 μM Na3VO4, 1.5 mM DTT, and 0.5 mM Trasylol (buffer M) with 1% Nonidet P-40, 0.1 mM EGTA, and 5 mM dithiothreitol. All fractions were adjusted to RIPAVF conditions. Detergent-insoluble material resulting from procedure c was fractionated further by a modification of the procedure reported by Staufenbiel and Deppert (54): a 15-min treatment at 4°C with 400 μl buffer containing 1 mM CaCl2, 30-min treatment at 4°C with 400 μl buffer containing 2 M NaCl, 1 mM EGTA, and 5 mM dithiothreitol. All fractions were adjusted to RIPAVF conditions.

**Immunoperoxidase Staining**

The procedures for frozen tissue preparation and immunoperoxidase staining were exactly as described previously (30). Photographs were taken with Kodak technical black and white film.
Results

Ezrin Is Homologous to the Protein-Tyrosine Kinase Substrate, p81

The unphosphorylated form of the phosphotyrosine-containing 81-kD protein (p81) in A431 cells has been previously identified by its migration on two-dimensional gels (13). Because the position of p81 relative to actin on our two-dimensional gels was very similar to that reported for intestinal ezrin (3), we decided to investigate a possible homology. To do this we made use of an antiserum raised against chick intestinal ezrin that had been shown to react with a similar protein in a wide variety of species (3).

We first determined whether A431 cells contained a protein that could be immunoprecipitated by anti–ezrin serum. [35S]Methionine-labeled A431 cells were lysed in RIPA-VF buffer and subjected to immunoprecipitation with either nonimmune serum or anti–ezrin serum. After SDS polyacrylamide gel electrophoresis, we observed a predominant, specifically immunoprecipitated, protein with an apparent molecular mass of 81,000 (Fig. 1) that comprised ~0.03% of the total [35S]methionine-labeled protein (see Materials and Methods). A minor protein with an apparent molecular mass of 120,000 was also specifically immunoprecipitated (Fig. 1). When lysates were prepared in SDS lysis buffer rather than RIPA-VF buffer, the 120-kD protein was no longer apparent in immunoprecipitates nor was it detected on Western blots. Analysis of glycerol gradients, in which RIPA-VF lysates of [35S]methionine-labeled A431 cells had been sedimented, showed the 81-kD protein to have the sedimentation rate expected for a protein this size (data not shown). The 120-kD protein exhibited a higher sedimentation value than did the 81-kD protein, indicating that it was not complexed with this protein but rather was recognized independently by the antiserum. Two-dimensional tryptic peptide analysis of the [35S]methionine-labeled 120-kD protein revealed that it was not related to the 81-kD protein (data not shown). Furthermore, affinity purified anti–ezrin Ig did not immunoprecipitate the 120-kD protein. Thus, a single 81-kD protein in A431 cells appeared to be homologous to ezrin.

Two different experiments were performed to test the relatedness of the 81-kD protein immunoprecipitated by anti–ezrin serum and p81. For reference, the spot on a two-dimensional gel of [35S]methionine-labeled A431 cells that corresponds to the previously identified unphosphorylated form of p81 is indicated with an arrow in Fig. 2A (13). In the first experiment, immunoprecipitates of [35S]methionine-labeled A431 cell proteins, prepared either with a nonimmune serum or with anti–ezrin serum, were mixed with total unlabelled A431 cell proteins and resolved by two-dimensional gel electrophoresis. The gels were first silver-stained to display the pattern of unlabeled proteins (Fig. 2B), and labeled proteins were detected by fluorography (Fig. 2C). Alignment of the fluorographs with silver-stained gels demonstrated that the 81-kD protein recognized by anti–ezrin serum co-migrated with p81. In the second experiment, total [35S]methionine-labeled A431 cell proteins were separated by two-dimensional gel electrophoresis and electrophoretically transferred to a nitrocellulose sheet. The blot was probed with anti–ezrin serum followed by 125I-labeled Staphylococcal protein A. 125I-Protein A bound specifically to only one spot, which co-migrated with the major unphosphorylated form of p81 (data not shown).

To establish further the relatedness of the microvillar core protein and p81, the tryptic peptides of [35S]methionine-labeled p81 immunoprecipitated from LIM1215 cells, a human colonic tumor cell line that possesses microvilli (55), primary chicken embryo cells, and human A431 cells were compared. The large number of tryptic peptides shared by p81 from chicken and human cells (>50%) demonstrated that this protein has been highly conserved throughout evolution (Fig. 3, A–C). The identical pattern of tryptic peptides gen-
Figure 2. Migration of A431 cell p81 on two-dimensional gels. A431 cells were labeled with [35S]methionine and solubilized in two-dimensional gel sample buffer. Proteins were resolved by two-dimensional gel electrophoresis as described in Materials and Methods with pH 6-8 range amphotoles and visualized by fluorography (A). In a second experiment, ~10 µg of protein from unlabeled A431 cells was mixed with a [35S]methionine-labeled anti-ezrin immunoprecipitate from A431 cells and resolved by two-dimensional gel electrophoresis with pH 6-8/10 range amphotoles. The gel was silver stained (B) and then subjected to fluorography (C). Relevant portions of the gels are shown. Note that silver staining decreases the efficiency of fluorography. Acidic proteins are on the left. Arrowheads point to actin (A) and to p81. Exposure times were 18 h (A) and 5 d (C).

Figure 3. Two-dimensional tryptic peptide maps of p81 from A431, chicken embryo, and LIM1215 cells. p81 was immunoprecipitated with anti-ezrin serum from [35S]methionine-labeled A431 cells, LIM1215 cells, and chicken embryo cells and subjected to tryptic cleavage. The resultant peptides were resolved in two dimensions as described in Materials and Methods. p81 from: (A) A431 cells; (B) chicken embryo cells; (C) A431 and chicken embryo cells mixed; (D) A431 cells; (E) LIM1215 cells; (F) A431 and LIM1215 cells mixed. A–C and D–F are from different experiments. In each case the origin is marked with an arrowhead. Electrophoresis was performed at pH 4.7 in the horizontal dimension, with the anode on the left. Plates were impregnated with 2-methyl-naphthalene and exposed at -70°C. cpm loaded onto thin layer plates and exposure times are as follows: (A) 18,000 cpm, 5 d; (B) 3,500 cpm, 2 wk; (C) 3,500 cpm of each, 10 d; (D) 31,000 cpm, 3 d; (E) 39,000 cpm, 3 d; (F) 13,000 cpm of each, 3 d.
erated from A431 p81 and LIM1215 p81 (Fig. 3, D–F) indicated that no unusual modification of p81 occurs in intestinal cells.

**Intracellular Distribution of p81 in A431 Cells**

Since ezrin was purified as a component of the microvillar core (3), we anticipated that p81 would be found in microvilli of A431 cells and would behave in biochemical fractionations as if it were a component of the A431 cytoskeleton. We attempted to confirm these predictions with both indirect immunofluorescence and biochemical fractionation. In addition, we asked whether or not EGF treatment and/or phosphorylation altered the distribution of p81.

Because of the unwanted specificity in the anti-ezrin serum towards the unrelated 120-kD protein, affinity-purified Ig which does not recognize this protein was used for immunofluorescence staining. p81 in A431 cells was concentrated in surface projections such as microvilli and retraction fibers (Fig. 4). This pattern was more pronounced when cells were grown on poly-D-lysine-coated coverslips (Fig. 4 C). It was not detectable unless the cell membrane was permeabilized (data not shown). This pattern of p81 staining in A431 cells is similar to that observed in other tissue culture cells (3).

To determine the degree of association between p81 and the cytoskeleton, three different detergent extraction conditions reported to leave the cytoskeleton intact were applied to A431 cells (6, 11, 54). [35S]Methionine-labeled or 32P-labeled cells treated with or without EGF were extracted under these three conditions. In addition, we determined whether or not p81 was in the soluble or particulate fractions of cells lysed by homogenization after swelling in hypotonic buffers containing either MgCl₂ or EDTA. After all the fractions had been adjusted to RIPA-VF conditions, p81 was immunoprecipitated with excess anti-ezrin serum, and the percentages of p81 in each fraction were estimated by counting gel bands and scanning autoradiographs (Table I). Between 37 and 61% of p81 was insoluble depending on the procedure. The distribution of the phosphorylated form of the protein (pp81) paralleled that of the total p81 population. In addition, treatment of the cells with EGF did not appear to alter the distribution of p81 (Table I). The greatest percentage of p81 was found associated with the cytoskeleton prepared using procedure c (see Materials and Methods). This insoluble material was further fractionated by incubation with DNase I, followed by a Ca²⁺ extraction, and then a 2 M NaCl extraction. SDS polyacrylamide gel analysis of proteins from each extract and the residual material illustrated that each extract contained a significantly different population of proteins (data not shown). This suggested that nonspecific leaching out of proteins during this long procedure was minimal. As additional controls, the fractionation properties of fodrin, a cortical cytoskeletal protein (27), and another protein-tyrosine

**Figure 4.** Indirect immunofluorescent staining with affinity-purified anti-ezrin Ig in A431 cells. A431 cells were grown on glass coverslips uncoated (A) or coated (C) with poly-D-lysine. They were incubated with affinity-purified anti-ezrin Ig followed by affinity-purified fluorescein-conjugated goat anti-rabbit IgG as described in Materials and Methods. Nomarski images of A and C are shown in B and D, respectively. Bar, 12 μm.
A431 cells were labeled with \[^{35}S\]methionine or \[^{32}P\]orthophosphate and were either untreated or treated with EGF at 60 ng/ml for 10 min. The cells were lysed according to one of five procedures detailed in Materials and Methods and separated into soluble and particulate fractions. All resultant fractions were adjusted to RIPA-VF conditions. \[^{35}S\]labeled p81 and \[^{32}P\]labeled p81 were immunoprecipitated from each fraction and resolved on 12.5% polyacrylamide gels. After fluorography or autoradiography, the percentages of \[^{35}S\]labeled p81 and \[^{32}P\]labeled p81 in each fraction were determined by counting solubilized gel bands and by scanning autoradiographs. Only values for the particulate fractions are shown. There is about five times more p81 in EGF-treated A431 cells than in control cells (see Fig. 8). The data for distribution of p81 include only a small (~10%) contribution from p81. The numbers provided for \[^{32}P\]labeled p81 are the average of results obtained by the two methods of data analysis described from one experiment. This experiment was repeated with another protein, that protein would have to be small enough so as not to cause a detectable shift in the sedimentation of p81. Alternatively, its association with another protein might be sensitive to the hydrodynamic forces encountered during the centrifugation.

### Table I. Distribution of p81 and pp81 between A431 Cell Fractions

| Procedure | p81 | pp81 |
|-----------|-----|------|
| -EGF      |     |      |
| +EGF      |     |      |
| % particate |     |      |
| Procedure a | 42  | 45  |
| Procedure b | 37  | 43  |
| Procedure c | 61  | 68  |
| Hypotonic lysis | 48  | 54  |
| Mg\(^{2+}\) | 49  | 46  |
| EDTA      | 56  | 59  |

Table II. Distribution of Fodrin, p81, and p36 in Sequential Extractions of A431 Cells

| Extractions | Fodrin | p81 | p36 |
|-------------|--------|-----|-----|
| 1% Nonidet P-40 | 27    | 21  | 29  |
| 50 \(\mu\)g/ml DNase I | 9    | 18  | 20  |
| 1 mM Ca\(^{2+}\) | 5    | 19  | 4   |
| 2 M NaCl | 13   | 19  | 22  |
| Residual material | 46  | 23  | 25  |

Gould et al. Protein-Tyrosine Kinase Substrate p81
Figure 6. Western blot of adult mouse tissues. Protein from each tissue was resolved on a 15% polyacrylamide gel. Proteins were electrophoretically transferred to nitrocellulose sheets, incubated with anti-ezrin serum, and then probed with ^125I-protein A. Lane 1, 2 μg small intestine; lane 2, 5 μg small intestine; lane 3, 10 μg small intestine; lane 4, 20 μg small intestine. Lanes 5–17 were loaded with 20 μg of protein from: lane 5, brain; lane 6, liver; lane 7, kidney; lane 8, lung; lane 9, heart; lane 10, thigh muscle; lane 11, fascia; lane 12, bone marrow cells; lane 13, spleen; lane 14, lymph node; lane 15, thymus; lane 16, testes; lane 17, urinary tract. Exposure time was 18 h with an intensifying screen at −70°C.

Figure 7. Indirect immunoperoxidase staining of p81 in rat spleen and thymus. Frozen tissue sections of rat spleen (A and B) and rat thymus (C and D) were incubated with affinity-purified anti-ezrin Ig followed by affinity-purified horseradish peroxidase–conjugated goat anti-rabbit IgG and diaminobenzidine as described in Materials and Methods (A and C). B and D show photographs of similar sections stained only with the second layer antibodies and diaminobenzidine. Bar, 12 μm.

personal communication). To determine whether there is a subpopulation of cells that accounts for the high expression of p81 in thymus and spleen, frozen tissue sections of each organ from rat were prepared for indirect immunoperoxidase staining using affinity-purified anti-ezrin Ig. Stained sections of each organ are shown in Fig. 7. In the spleen, periarterior lymphocytes stain strongly as do small B cells and large B cell blasts. Some lymphocytes in the red pulp are also positive. Structural cells and megakaryocytes were weakly positive. Red cell and white cell precursors, red cells, and endothelial cells do not stain (Fig. 7A). In the thymus, p81 is most prevalent in subcapsular lymphocytes (Fig. 7B). Lymphocytes from the medulla stain more strongly than those from the cortex. The epithelial reticular cells are weakly reactive. These data suggest that the expression of p81 is not restricted to cell types with highly organized microvilli.

p81 Can Be Phosphorylated on Serine, Threonine, and Tyrosine Residues

Using the anti-ezrin serum, we investigated the phosphorylation state of p81 in A431 cells. Subconfluent A431 cells were labeled with ^32P-orthophosphate at 37°C for 18 h and then treated with EGF for 10 min. After lysis of the cells in
RIPA-VF, p81 was immunoprecipitated with anti-ezrin serum (Fig. 8A). Untreated cells contained detectable levels of phosphorylated p81. EGF treatment increased the phosphate labeling of p81 about fivefold (Fig. 8A, lanes 1 and 2). When the gel shown in Fig. 8A was then incubated in alkali to enhance detection of phosphothreonine and phosphotyrosine residues (Fig. 8B), alkali-stable radioactivity was detectable in p81 from untreated cells. p81 from unstimulated cells, isolated in the presence of phosphatase inhibitors, was found to contain phosphoserine and phosphothreonine, whereas p81 from EGF-stimulated cells contained phosphoserine, an increased amount of phosphothreonine, and phosphotyrosine (Fig. 8C, a and b). Alkali-stable radioactivity, however, was only detectable in p81 from untreated cells if phosphatase inhibitors were included in the lysis buffer. This would explain our earlier results where p81 was not detected on alkali-treated two-dimensional gels of untreated cells (34). Apparently a phosphothreonine-specific phosphatase in A431 cells is active on p81 during two-dimensional gel sample preparation and also in unmodified RIPA buffer.

The fraction of p81 newly modified at tyrosine in response to EGF treatment was estimated in the following manner. Anti-ezrin immunoprecipitates of [32P]methionine-labeled control and EGF-stimulated A431 cells (prepared in unmodified RIPA buffer and thus lacking detectable levels of phosphothreonine) were resolved on two-dimensional gels. The fluorographs of these gels were quantified by two-dimensional computer-assisted densitometry. The percentage of phosphorylated p81, which migrates to a more acidic position than the majority of the protein, was calculated to be 10% in EGF-treated cells. This percentage represents a minimum estimate since it is likely that some phosphotyrosine was lost in addition to the phosphothreonine due to protein phosphatase action in unmodified RIPA buffer.

The phosphorylation sites of p81 were investigated by two-dimensional tryptic peptide analysis of p81 immunoprecipitated in the presence of phosphatase inhibitors. p81 isolated from control cells contained three major phosphopeptides termed 1, 2, and 3 (Fig. 9A). Phosphopeptides 1 and 2 contained only phosphothreonine, whereas phosphopeptide 3 contained phosphothreonine and phosphoserine (data not shown). p81 from stimulated cells contained phosphopeptides 1–3 and one major new phosphopeptide termed phosphopeptide 4 (Fig. 9B). Phosphopeptide 4 contained phosphotyrosine exclusively (data not shown).

**Discussion**

In this study, we have characterized a protein-tyrosine kinase substrate in A431 cells that has a molecular mass of 81,000. p81 is homologous to the intestinal protein ezrin, and may indeed be identical. Like ezrin in intestinal epithelial cells, p81 is localized in the submembranous cortical skeleton where it is concentrated in microvilli. We obtained no evidence that p81 is specifically associated with any other cellular protein.
The protein has been highly conserved throughout evolution. In the mouse, p81 is found in a wide variety of tissues.

In many ways our findings with p81 parallel what is known about another protein tyrosine kinase substrate, p36. First, both are concentrated in the apical cytoskeletal region of intestinal brush border cells (25, 30, 32), indicating that they are associated with structural components. p81, and under some conditions p36 (7, 11, 48), fractionate with cytoskeletal elements when tissue culture cells are extracted with detergent. These properties are consistent with the notion that p81 and p36 are either part of the cytoskeletal framework or associated with cytoskeletal proteins in detergent-insoluble fractions. However, we have been unable to demonstrate binding of soluble p81 to other proteins in sedimentation studies under a variety of conditions. Similarly, reconstitution studies of microvillar core proteins have not provided evidence for specific association with other proteins (Bretscher, A., unpublished results). p81 binding to detergent-insoluble fractions is not divalent cation dependent. This is in contrast to p36, which has been found in dimeric form in association with a 10-kD protein (22, 23) and has also been shown to bind actin and fodrin in a Ca2+-dependent manner (25, 29). The fractionation properties of p81 do not appear to change significantly when the protein is phosphorylated in response to EGF. However, without a more complete understanding of the function of p81, subtle changes in distribution or associations cannot be ruled out.

As well as exhibiting similar intracellular distributions, p81 and p36 appear to have similar anatomical distributions in the mouse. Both proteins are expressed at very low levels in brain, muscle, and liver with high levels in intestine, thymus, and lung (30). Neither protein co-distributes in tissues with any known protein-tyrosine kinase (1, 19, 37, 53, 56), although in A431 cells examined by indirect immunofluorescence, the distributions of p81 and p36 overlap that of the EGF receptor (Gould, K. L., unpublished results). This would be consistent with p81 being a primary substrate for the EGF receptor protein-tyrosine kinase. We do not yet know if there is an active protein-tyrosine kinase located in the small intestine or if p81 or p36 is phosphorylated on tyrosine there.

The results of the gross anatomical survey concealed some differences between p81 and p36 that were found when the cell types expressing each protein were identified. In the thymus, for example, p36 is located predominantly in the structural framework of the organ (30), whereas p81 is found in the lymphocytes and only at low levels in the epithelial cells. In addition the level of p81 in kidney is considerably higher than that of p36. This may be of relevance in the microvillar structures of kidney proximal tubules.

p81 is phosphorylated in A431 cells on serine and threonine residues. In response to EGF, ~10% of the protein is additionally phosphorylated on tyrosine residues, and the extent of threonine phosphorylation increases. Tryptic digestion of pp81 from EGF-treated cells reveals only one major phosphotyrosine-containing peptide, suggesting a single site of tyrosine phosphorylation. This study of the phosphorylation sites in p81 demonstrated the need for specific phosphatase inhibitors in lysis buffers. In the absence of sodium fluoride and sodium orthovanadate, pp81 from untreated cells was barely detectable and contained only phosphoserine. In response to EGF, p81 was additionally phosphorylated on tyrosine. However, when isolated in the presence of phosphatase inhibitors, pp81 from untreated cells was readily detectable and contained phosphothreonine and phosphoserine. Its phosphorylation on threonine as well as on tyrosine was stimulated by EGF treatment. Phosphorylation of the threonine site(s) is probably not due to activation of protein kinase C in EGF-treated A431 cells as purified p81 is neither phosphorylated by protein kinase C in vitro nor phosphorylated to a greater extent in vivo in response to tumor promoters (Gould, K. L., and J. Meisenhelder, unpublished results). It is also worth noting here that despite their similarity in size and subcellular location, p81 is unlikely to be protein kinase C. Indirect evidence for this includes their very different tissue distributions (41), their different pls (38), their distinct intracellular distributions (45), and the inability of purified p81 to act as a protein kinase in vitro. More direct evidence is the disparate two-dimensional phosphopeptide maps of the two proteins (our unpublished results).

p81 appears to be the product of a single gene. In vitro translation of poly A-containing RNA from a number of rodent cell and tissue sources followed by immunoprecipitation yielded a single protein that in every case co-migrated on one- and two-dimensional gels with p81 from metabolically labeled rodent cells (Saris, C., personal communication). Thus, the protein does not appear to be synthesized as a precursor. p81 is also a very stable protein with a half-life of ~17 h. Although it is abundant, comprising ~0.03% of the total cell protein in A431 cells, it is 5-10-fold less abundant than p36 (17, 47). Due to this lower abundance, pp81 may have been overlooked in other studies searching for substrates of tyrosine phosphorylation. Indeed, by immunoprecipitation, but not by two-dimensional gel analysis, we have been able to identify a phosphotyrosine-containing form of p81 in Rous sarcoma virus-transformed chicken cells (Gould, K. L., unpublished results). We are currently investigating under what other conditions p81 is phosphorylated on tyrosine.

Without a functional assay for p81 we cannot assess whether phosphorylation of p81 is likely to be of consequence in the response of cells to EGF or in viral transformation. The relatively low stoichiometry of p81 tyrosine phosphorylation could be of significance if a critical subpopulation of the protein were phosphorylated. Alternatively p81 might be phosphorylated gratuitously as a consequence of its proximity to a variety of membrane-associated protein-tyrosine kinases. The answer to this question must await further studies on the structure and function of p81.

We thank David Schubert for his computer analysis of two-dimensional gel fluorographs, Robert Whitehead for the gift of LIM1215 cells, Jim Woodgett for critical reading of the manuscript, and John Glenney for his gift of anti-fodrin serum.

This work was supported by U. S. Public Health Service Grants CA17096 and CA28458 to T. Hunter and National Science Foundation grant PCM-8317832 and American Cancer Society grant CD-194 to A. Bretscher. K. L. Gould was supported by a National Institutes of Health predoctoral training grant to the University of California at San Diego.

Received for publication 4 September 1985.

References

1. Adamson, E. D., M. J. Deller, and J. B. Warshaw, 1981. Functional EGF receptors are present on mouse embryo tissues. Nature (Lond.). 291:656–659.
2. Beemon, K. and T. Hunter. 1978. Characterization of Rous sarcoma virus protein kinase activity in vitro. J. Virol. 28:551-556.

3. Groesbeck, J. and R. A. Coffey. 1983. Purification of a 40,000-dalton protein that is a component of the isolated microvillus cytoskeleton, and its localization in nonmuscle cells. J. Cell Biol. 97:425-432.

4. Bretscher, A. 1983. The molecular architecture of the microvillus cytoskeleton. Cytobiology 24:95-164.

5. Brugge, J. and D. Darrow. 1982. Rous sarcoma virus-induced phosphorylation of a 50,000 molecular weight cellular protein. Nature (Lond). 295:250-253.

6. Burr, J. G., G. Dreyfuss, S. Penman and J. M. Buchanan. 1980. Association of the src gene product of Rous sarcoma virus with cytoskeletal structures of chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA. 77:3484-3488.

7. Cheng, Y-S. E. and L. B. Chen. 1981. Detection of phosphotyrosine-containing 34,000-dalton protein in the framework of cells transformed with Rous sarcoma virus. Proc. Natl. Acad. Sci. USA. 78:2388-2392.

8. Cooper, J. A. and T. Hunter. 1981. Changes in protein phosphorylation in Rous sarcoma virus transformed chicken embryo cells. Mol. Cell. Biol. 1:165-178.

9. Cooper, J. A. and T. Hunter. 1981. Four different classes of retroviruses induce phosphorylation of tyrosines present in similar cellular proteins. Mol. Cell. Biol. 1:394-407.

10. Cooper, J. A., D. F. Bowen-Pope, E. Raines, R. Ross and T. Hunter. 1982. Similar effects of platelet-derived growth factor and epidermal growth factor on the phosphorylation of tyrosine in cellular proteins. Cell. 31:263-273.

11. Cooper, J. A. and T. Hunter. 1982. Discrete primary locations of a tyrosine protein kinase and of three proteins that contain phosphotyrosine in virally transformed chick cells. J. Cell Biol. 94:287-296.

12. Cooper, J. A. and T. Hunter. 1983. Regulation of cell growth and transformation by src-related protein kinases. In Rous Sarcoma Viruses. M. M. Greenberg, E. R. Brackenbury and G. M. Edelman. 1983. Changes in the distribution of the 34-kilodalton tyrosine kinase substrate during differentiation and maturation of chicken tissues. J. Cell Biol. 98:473-486.

13. Hunter, T. and B. M. Sefton. 1980. Transforming gene product of Rous sarcoma virus phosphorylates tyrosine. Proc. Natl. Acad. Sci. USA. 77:1311-1315.

14. Hunter, T. and J. A. Cooper. 1981. Epidermal growth factor induces rapid tyrosine phosphorylation of proteins in A431 human tumor cells. Cell. 24:741-753.

15. Hunter, T. and B. M. Sefton. 1980. Protein kinases and viral transformation. In Molecular Actions of Toxins and Viruses. P. Cohen and S. Van Heyningen, editors. Elsevier/North Holland Biomedical Press. Amsterdam. 373-385.

16. Hunter, T. and J. A. Cooper. 1983. Role of tyrosine phosphorylation in malignant transformation by viruses and in cellular growth control. Prog. Nucleic Acid Res. Mol. Biol. 29:221-233.

17. Jacobs, C. and H. Rübsamen. 1983. Expression of pp60src protein kinase in adult and fetal human tissue: high activities in some sarcomas and mammary carcinomas. Cancer Res. 43:1696-1702.

18. Kikkawa, U., Y. Takai, R. Minakuchi, S. Inohara and Y. Nishizuka. 1982. Calcium-activated, phospholipid-dependent protein kinase from rat brain. J. Biol. Chem. 257:13341-13348.

19. Klairlund, J. K. 1985. Transformation of cells by an inhibitor of phosphatases acting on phosphotyrosine in proteins. Cell 41:707-717.

20. Cotton, P. C. and J. S. Brugge. 1983. Neural tissues express high levels of a pp60src protein kinase substrate. J. Biol. Chem. 258:1108-1115.

21. Erikson, E., and R. L. Erikson. 1980. Identification of a cellular protein kinase which is related to the src gene of avian sarcoma virus. Mol. Cell. Biol. 1:157-162.

22. Cooper, J. A., N. A. Reiss, R. J. Schwartz and T. Hunter. 1983. Three glycolytic enzymes are phosphorylated at tyrosine in cells transformed by Rous sarcoma virus. Nature (Lond). 302:218-223.

23. Cooper, J. A., E. M. Scolnick, B. Ozanne and T. Hunter. 1983. Epidermal growth factor receptor metabolises and protein kinase activity in human A431 cells infected with Snyder-Theilen feline sarcoma virus or Harvey or Kirsten murine sarcoma virus. J. Virol. 48:752-764.

24. Cooper, J. A., B. M. Sefton and T. Hunter. 1983. Detection and quantification of phosphotyrosine in proteins. Methods Enzymol. 99:387-402.

25. Cooper, J. A., B. M. Sefton and T. Hunter. 1984. Diverse mitogenic agents induce the phosphorylation of two related 42,000-dalton proteins on tyrosine in quiescent chick cells. Mol. Cell. Biol. 4:30-37.

26. Cooper, J. A., B. M. Sefton and T. Hunter. 1984. Mitogenic agents induce the phosphorylation of a 34-kilodalton substrate of tyrosine protein kinases to the cytoplasmic surface of the plasma membrane. J. Cell Biol. 96:1601-1609.

27. Nishizuka, Y. 1984. The role of protein kinase C in cell surface signal transduction and tumour promotion. Anal. Biochem. 117:307-310.

28. Nakamura, K. D., R. Martinez and M. J. Weber. 1983. Tyrosine phosphorylation of specific proteins following mitogen stimulation of chicken embryo fibroblasts. Mol. Cell. Biol. 3:380-390.

29. Nigg, E. A., J. A. Cooper and T. Hunter. 1983. Immunofluorescent localization of a 39,000-dalton substrate of tyrosine protein kinases to the cytoplasmic surface of the plasma membrane. J. Cell Biol. 97:1601-1609.

30. Hunter, T. and J. A. Cooper. 1983. Role of tyrosine phosphorylation in malignant transformation by viruses and in cellular growth control. Prog. Nucleic Acid Res. Mol. Biol. 29:221-233.

31. Opperman, H. A., D. Levinson, L. E. Varmus, J. M. Bishop and S. Kawai. 1981. Two cellular proteins that immunoprecipitate with the transforming protein of Rous sarcoma virus. Virology. 113:736-751.

32. Radke, K., T. Gilmore and G. S. Martin. 1980. Transformation by Rous sarcoma virus: a cellular substrate for transformation-specific protein phosphorylation contains phosphotyrosine. Cell. 21:83-92.

33. Radke, K., V. C. Carter, P. Moss, P. Dehazya, M. Schiwa, and G. S. Martin. 1983. Mitogen-dependent localization of a 39,000-dalton substrate for tyrosine protein kinases to the cytoplasmic surface of the plasma membrane. J. Cell Biol. 97:1601-1609.

34. Sefton, B. M., K. Beemon and T. Hunter. 1978. Expression of the src gene of Rous sarcoma virus in vitro and in vivo. J. Virol. 28:957-961.

35. Sefton, B. M., T. Hunter, K. Beemon, and W. Eckhart. 1980. Evidence that the phosphorylation of tyrosine is essential for cellular transformation by Rous sarcoma virus. Cell. 20:807-816.

36. Sefton, B. M., T. Hunter, E. H. Ball and J. S. Singer. 1981. A cytoskeletal substrate of the transforming protein of Rous sarcoma virus. Cell. 24:165-174.

37. Sefton, B. M., T. Hunter, E. Niggs, J. S. Singer, and G. Walter. 1981. Cytoskeletal targets for viral transforming proteins with tyrosine kinase activity. Cold Spring Harbor Symp. Quant. Biol. 46:299-351.

38. Shibuya, M., H. Hanafusa and P. C. Balduzzi. 1982. Cellular sequences related to three new onc genes of avian sarcoma virus (src, yes, and ras) and their expression in normal and transformed cells. J. Cell Sci. 42:143-152.

39. Staeheli, M. and W. Dapper. 1983. Different structural systems of the nucleus are targets for SV40 large T antigen. Cell. 33:173-181.

40. Whitehead, R. H., F. A. Macrae, D. J. B. St. John, and J. Ma. 1985. A colon cancer cell line (LM1/215) derived from a patient with inherited nonpolyposis colorectal cancer. J. Cell Sci. 74:269-275.

41. Witte, O. N., N. Rosenberg, and D. Baltimore. 1979. A normal cell protein cross-reactive to the major Abelson murine leukemia virus gene product. Nature (Lond). 281:396-398.